Key facts
- Hemanext’s last known valuation is $115.0M (Oct 2024).
- It has raised $220.3M across 6 recorded rounds; the latest was Early Stage VC ($20.0M) in Jul 2025.
- Notable investors include Eduardo Avayu Family Office, Grabe Family Office, Omega Advisors, Testa Family Office, Antaeus Enterprises — 12 tracked in total.
- Hemanext has filed 7 Form Ds with the SEC since 2020, most recently Aug 2025 ($20.0M sold to 29 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 6 rounds
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Hemanext
Funding rounds
6 roundsAbout Hemanext
Developer of transfusion medical technology designed to support the transfusion medicine community in efforts to save lives and improve patient outcomes. The company offers novel storage methods to potentially extend the shelf life of refrigerated red blood cells while enhancing the quality across the storage cycle, enabling healthcare providers to promote improvements in the quality, safety, and efficacy, and reduce the cost of transfusion therapy.
- Sector
- Healthcare
- HQ
- Lexington, MA, United States
- Founded
- 2000
- Employees
- 52
- Website
- hemanext.com/
- Ownership
- Privately Held (backing)
Hemanext doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Hemanext shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Hemanext in its N-PORT filings yet. We sweep new filings monthly.